scholarly journals Computational and Pharmacological Investigation of (E)-2-(4-Methoxybenzylidene)Cyclopentanone for Therapeutic Potential in Neurological Disorders

2020 ◽  
Vol Volume 14 ◽  
pp. 3601-3614
Author(s):  
Sabah Farooq ◽  
Arif-ullah Khan ◽  
Muhammad Shahid Iqbal
Keyword(s):  
Neurological Disorders ◽  
Therapeutic Potential ◽  
Pharmacological Investigation

scholarly journals mRNA-Driven Generation of Transgene-Free Neural Stem Cells from Human Urine-Derived Cells

Cells ◽  
2019 ◽  
Vol 8 (9) ◽  
pp. 1043 ◽  
Author(s):  
Phil Jun Kang ◽  
Daryeon Son ◽  
Tae Hee Ko ◽  
Wonjun Hong ◽  
Wonjin Yun ◽  
...  
Keyword(s):  
Stem Cells ◽  
Neural Stem Cells ◽  
Human Urine ◽  
Neurological Disorders ◽  
Therapeutic Potential ◽  
Embryonic Stem ◽  
Global Gene Expression ◽  
Patient Specific ◽  
Human Neural Stem Cells

Human neural stem cells (NSCs) hold enormous promise for neurological disorders, typically requiring their expandable and differentiable properties for regeneration of damaged neural tissues. Despite the therapeutic potential of induced NSCs (iNSCs), a major challenge for clinical feasibility is the presence of integrated transgenes in the host genome, contributing to the risk for undesired genotoxicity and tumorigenesis. Here, we describe the advanced transgene-free generation of iNSCs from human urine-derived cells (HUCs) by combining a cocktail of defined small molecules with self-replicable mRNA delivery. The established iNSCs were completely transgene-free in their cytosol and genome and further resembled human embryonic stem cell-derived NSCs in the morphology, biological characteristics, global gene expression, and potential to differentiate into functional neurons, astrocytes, and oligodendrocytes. Moreover, iNSC colonies were observed within eight days under optimized conditions, and no teratomas formed in vivo, implying the absence of pluripotent cells. This study proposes an approach to generate transplantable iNSCs that can be broadly applied for neurological disorders in a safe, efficient, and patient-specific manner.

The Therapeutic Potential of Statins in Neurological Disorders

2007 ◽  
Vol 14 (1) ◽  
pp. 103-112 ◽  
Author(s):  
G. Rajanikant ◽  
D. Zemke ◽  
M. Kassab ◽  
A. Majid
Keyword(s):  
Neurological Disorders ◽  
Therapeutic Potential

scholarly journals Neuroprotective Effects, Biological Activities and Therapeutic Potential of Phytochemicals: A Comprehensive Review

2020 ◽  
pp. 1-11
Author(s):  
Xi-jun Wang ◽  
Shi Qiu ◽  
Aihua Zhang ◽  
Jian-hua Miao ◽  
Hui Sun ◽  
...  
Keyword(s):  
Natural Products ◽  
Neurological Disorders ◽  
Chemical Biology ◽  
Therapeutic Potential ◽  
Biological Activities ◽  
Therapeutic Agents ◽  
Neuroprotective Effects ◽  
Alternative Medicines ◽  
Pharmacological Targets ◽  
The World

The incidence of neurological disorders is growing in the world together with an increased lifespan. Nowadays, there are still no effective treatments for neurodegenerative pathology, which make necessary to search for new therapeutic agents. Natural products, most of them used in phytochemicals from herbal medicine, are considered promising alternatives for the treatment of neurodegenerative diseases. Numerous herbs have been applied to neurodegenerative disease treatments as complementary and alternative medicines. In the 21st century, omics-coupled functional pharmacology was developed for neurodegenerative drug discovery from natural products. In this article, we firstly provide the latest understanding of neurological disorders on risk factors, category, diagnosis and treatment, and then specially present an overview of natural products in neuroprotective effects research from chemical biology to pharmacological targets, and also discuss the natural products application and future challenge.

scholarly journals Therapeutic Potential of Fluoxetine in Neurological Disorders

2008 ◽  
Vol 14 (2) ◽  
pp. 153-164 ◽  
Author(s):  
Jop P. Mostert ◽  
Marcus W. Koch ◽  
Marco Heerings ◽  
Dorothea J. Heersema ◽  
Jacques De Keyser
Keyword(s):  
Neurological Disorders ◽  
Therapeutic Potential

Paraneoplastic disorders and neuroimmunology

2011 ◽  
Author(s):  
Neil Scolding
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Neurological Disorders ◽  
Therapeutic Potential ◽  
Immune Therapy ◽  
Clinical Consequences ◽  
Humanized Monoclonal Antibodies

The extraordinary expansion in the field of neuroimmunology witnessed in the last decade is not just in the number of neurological disorders now considered to have an immune basis, nor the depth of understanding of disorders long known to be ‘neuroimmune’. Nor is it in the number of antibodies discovered and now testable, nor in the range of new immune suppressant or modifying treatments now emerging or already available. It is of course all of these things, but it is also more than the sum of these parts. What we are currently privileged to witness is the coming together of immunological understanding, the neurobiology of disease, and rational immune therapy, or at least the beginning of this process. To take one isolated example, neurogenetics and neurophysiology taught us about the clinical consequences of channel disruption; laboratory-based neuroimmunology showed antibodies to be capable of producing comparable acquired disease; and it seems likely that specific anti-B-cell humanized monoclonal antibodies offer the therapeutic potential to remove these channel-disrupting antibodies. Neither of these steps could be described in the last edition, and one can imagine similar dramatic changes will emerge before the next.

Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights

2021 ◽  
Vol 19 ◽  
Author(s):  
Namrata Pramod Kulkarni ◽  
Bhupesh Vaidya ◽  
Acharan Narula ◽  
Shyam Sunder Sharma
Keyword(s):  
Caffeic Acid ◽  
Neurological Disorders ◽  
Therapeutic Potential ◽  
Caffeic Acid Phenethyl Ester ◽  
Depression And Anxiety ◽  
Age Related ◽  
Anti Cancer ◽  
Therapeutic Molecules ◽  
Conifer Trees ◽  
Lateral Sclerosis

: Neurological disorders like Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, amyotrophic lateral sclerosis, Huntington’s disease (HD), epilepsy, traumatic brain injury (TBI), depression and anxiety are responsible for thousands of deaths worldwide every year. With the increase in life expectancy, there has been a rise in the prevalence of these disorders. Age is one of the major risk factors for these neurological disorders and with the aged population is set to rise to 1.25 billion by 2050. There is a growing concern to look for new therapeutic molecules to treat age-related diseases. Caffeic acid phenethyl ester (CAPE) is a molecule obtained from a number of botanical sources such as the bark of conifer trees as well as propolis which is extracted from beehives. Though CAPE remains relatively unexplored in human trials, it possesses antioxidant, anti-inflammatory, antimitogenic and anti-cancer activities as shown by preclinical studies. Apart from this, it also exhibits tremendous potential for the treatment of neurological disorders through modulation of multiple molecular pathways and attenuation of behavioural deficits. In the present article, we have reviewed the therapeutic potential of CAPE and its mechanisms in the treatment of neurological disorders.

Sign in / Sign up

Export Citation Format

Share Document